Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by the end of September to early November 2025Phase 1/2 data announced by Staidson BioPharmaceuti ...

Consumer Reports and Unleaded Kids evaluated baby food brands for compliance with California’s AB899 requiring heavy metal ...

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

Conference call to provide business updates today, August 6 at 1:30 p.m. PT / 4:30 p.m. ET FOSTER CITY, Calif., August 06, ...

Ultragenyx Pharmaceutical RARE reported second-quarter 2025 loss of $1.17 per share, narrower than the Zacks Consensus ...

Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...

August 5, 2025Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported EPS is $0.681 EPS, expectations ...

Global breast imaging market projected to reach $8.69 billion by 2030, with IzoView addressing key clinical and commercial trends driving demand ...

Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 ...

Novo Nordisk NVO is scheduled to report its second-quarter 2025 results before the opening bell on Aug. 6, 2025. The Zacks ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.